This suggests that this extract might be a potential therapeutic agent to modulate OA [5]
Berner F, Bomze D, Diem S, and Ali OH, et al (2019) Association of checkpoint inhibitor-induced toxic effects with shared cancer and tissue antigens in non-small cell lung cancer JAMA Oncol 5 (7) 10431047 PMID: 31021392 PMCID: 6487908 45
Dosage Range & Frequency Administration Routes Suggested Usage Cycle Continuous use: 48 weeks After a cycle, discontinue or take a break
conditions relating to acute and/or chronic inflammation, in particular, chronic arthritis, and disorders related with delayed type of hypersensitivity, and gastrointestinal lesions
The most frequently reported adverse effects are gastrointestinal in nature and typically occur during the initial weeks of treatment or following dose increases